(MKL) Markel - Overview
Sector: Financial Services | Industry: Insurance - Property & Casualty | Exchange: NYSE (USA) | Market Cap: 23.249m USD | Total Return: -2.6% in 12m
Avg Turnover: 134M
EPS Trend: 83.2%
Qual. Beats: 0
Rev. Trend: 43.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Markel Group Inc. is a diverse holding company primarily focused on specialty insurance and reinsurance operations globally. The company provides a broad range of coverages, including professional liability, marine, energy, and catastrophe-exposed property insurance. Beyond its core underwriting business, Markel operates a diverse portfolio of non-insurance subsidiaries under its Markel Ventures division, spanning construction, manufacturing, and consulting services.
The business model utilizes an equity-focused investment strategy, where insurance float is reinvested into public equities and private acquisitions to drive long-term book value growth. This decentralized approach often draws comparisons to the Berkshire Hathaway model, as it balances volatile underwriting cycles with steady cash flows from industrial operations. Investors can further examine these capital allocation strategies by reviewing the detailed metrics available on ValueRay.
Headquartered in Virginia, the firm also manages third-party capital through insurance-linked securities and investment fund management. The 2023 name change to Markel Group Inc. reflects its evolution from a pure-play insurer into a diversified global conglomerate.
- Underwriting profitability in specialty insurance lines drives core operating cash flow
- Equity portfolio performance impacts book value growth and investment income
- Markel Ventures subsidiary earnings diversify revenue away from insurance cycles
- Catastrophic weather events increase loss ratios and pressure insurance margins
- Interest rate fluctuations influence fixed income yields and reinsurance pricing power
| Net Income: 1.77b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.16 > 1.0 |
| NWC/Revenue: -39.74% < 20% (prev 58.25%; Δ -97.99% < -1%) |
| CFO/TA 0.03 > 3% & CFO 2.40b > Net Income 1.77b |
| Net Debt (-6.48b) to EBITDA (2.48b): -2.61 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (11.2m) vs 12m ago -12.50% < -2% |
| Gross Margin: 61.44% > 18% (prev 0.56%; Δ 6.09k% > 0.5%) |
| Asset Turnover: 28.26% > 50% (prev 31.61%; Δ -3.35% > 0%) |
| Interest Coverage Ratio: 11.25 > 6 (EBITDA TTM 2.48b / Interest Expense TTM 204.7m) |
| A: -0.10 (Total Current Assets 33.6b - Total Current Liabilities 40.2b) / Total Assets 68.6b |
| B: 0.21 (Retained Earnings 14.7b / Total Assets 68.6b) |
| C: 0.04 (EBIT TTM 2.30b / Avg Total Assets 58.6b) |
| D: 0.59 (Book Value of Equity 18.1b / Total Liabilities 30.9b) |
| Altman-Z'' = 0.95 = BB |
| DSRI: 4.12 (Receivables 19.0b/4.28b, Revenue 16.6b/15.4b) |
| GMI: 0.91 (GM 61.44% / 55.73%) |
| AQI: 0.62 (AQ_t 0.48 / AQ_t-1 0.77) |
| SGI: 1.08 (Revenue 16.6b / 15.4b) |
| TATA: -0.01 (NI 1.77b - CFO 2.40b) / TA 68.6b) |
| Beneish M = -0.72 (Cap -4..+1) = D |
As of May 26, 2026, the stock is trading at USD 1857.89 with a total of 66,700 shares traded.
Over the past week, the price has changed by +0.75%,
over one month by -2.00%,
over three months by -10.53% and
over the past year by -2.63%.
Markel has received a consensus analysts rating of 3.29. Therefore, it is recommended to hold MKL.
- StrongBuy: 1
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 2005.4 | 7.9% |
P/E Trailing = 13.4406
P/E Forward = 12.285
P/S = 1.4519
P/B = 1.2822
P/EG = 1.8331
Revenue TTM = 16.6b USD
EBIT TTM = 2.30b USD
EBITDA TTM = 2.48b USD
Long Term Debt = 4.38b USD (from longTermDebt, last quarter)
Short Term Debt = 194.8m USD (from shortTermDebt, last fiscal year)
Debt = 4.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -6.48b USD (calculated: Debt 4.38b - CCE 10.9b)
Enterprise Value = 16.8b USD (23.2b + Debt 4.38b - CCE 10.9b)
Interest Coverage Ratio = 11.25 (Ebit TTM 2.30b / Interest Expense TTM 204.7m)
EV/FCF = 7.67x (Enterprise Value 16.8b / FCF TTM 2.19b)
FCF Yield = 13.04% (FCF TTM 2.19b / Enterprise Value 16.8b)
FCF Margin = 13.20% (FCF TTM 2.19b / Revenue TTM 16.6b)
Net Margin = 10.70% (Net Income TTM 1.77b / Revenue TTM 16.6b)
Gross Margin = 61.44% ((Revenue TTM 16.6b - Cost of Revenue TTM 6.39b) / Revenue TTM)
Gross Margin QoQ = 67.14% (prev 69.59%)
Tobins Q-Ratio = 0.24 (Enterprise Value 16.8b / Total Assets 68.6b)
Interest Expense / Debt = 4.67% (Interest Expense 204.7m / Debt 4.38b)
Taxrate = 21.24% (580.3m / 2.73b)
NOPAT = 1.81b (EBIT 2.30b * (1 - 21.24%))
Current Ratio = 0.84 (Total Current Assets 33.6b / Total Current Liabilities 40.2b)
Debt / Equity = 0.24 (Debt 4.38b / totalStockholderEquity, last quarter 18.1b)
Debt / EBITDA = -2.61 (Net Debt -6.48b / EBITDA 2.48b)
Debt / FCF = -2.96 (Net Debt -6.48b / FCF TTM 2.19b)
Total Stockholder Equity = 18.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.02% (Net Income 1.77b / Total Assets 68.6b)
RoE = 9.84% (Net Income TTM 1.77b / Total Stockholder Equity 18.0b)
RoCE = 10.27% (EBIT 2.30b / Capital Employed (Equity 18.0b + L.T.Debt 4.38b))
RoIC = 6.42% (NOPAT 1.81b / Invested Capital 28.2b)
WACC = 7.29% (E(23.2b)/V(27.6b) * Re(7.97%) + D(4.38b)/V(27.6b) * Rd(4.67%) * (1-Tc(0.21)))
Discount Rate = 7.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 75.88% ; FCFF base≈2.16b ; Y1≈2.23b ; Y5≈2.50b
[DCF] Fair Price = 3.60k (EV 38.6b - Net Debt -6.48b = Equity 45.1b / Shares 12.5m; r=8.35% [WACC [floored]]; 5y FCF grow 3.39% → 2.50% )
EPS Correlation: 83.15 | EPS CAGR: 21.82% | SUE: -0.71 | # QB: 0
Revenue Correlation: 43.38 | Revenue CAGR: 1.96% | SUE: -0.24 | # QB: 0
EPS current Quarter (2026-06-30): EPS=28.80 | Chg30d=-5.35% | Revisions=-14% | Analysts=4
EPS next Quarter (2026-09-30): EPS=27.27 | Chg30d=-4.40% | Revisions=-43% | Analysts=4
EPS current Year (2026-12-31): EPS=111.57 | Chg30d=-4.24% | Revisions=-43% | GrowthEPS=-0.5% | GrowthRev=-0.6%
EPS next Year (2027-12-31): EPS=121.74 | Chg30d=-4.23% | Revisions=-43% | GrowthEPS=+9.1% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: -43%